Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-04-20
2010-10-12
Helms, Larry R. (Department: 1642)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S350000, C424S198100
Reexamination Certificate
active
07811982
ABSTRACT:
The present invention provides a method of treating cancer involving administering an insulin-like growth factor-1 receptor (IGF-1 receptor) agonist and an anti-cancer chemotherapeutic agent. Also provided are compounds for treating cancer comprising an IGF-1-receptor ligand coupled to an anti-cancer chemotherapeutic agent. Also provided are compounds for treating cancer comprising an insulin-receptor ligand coupled to an anti-cancer chemotherapeutic agent.
REFERENCES:
patent: 4876242 (1989-10-01), Applebaum et al.
patent: 4975278 (1990-12-01), Senter et al.
patent: 5122368 (1992-06-01), Greenfield et al.
patent: 5444045 (1995-08-01), Francis et al.
patent: 5518888 (1996-05-01), Waldman
patent: 2003/0092631 (2003-05-01), Deshayes et al.
patent: 2003/0138430 (2003-07-01), Stimmel et al.
patent: 2004/0023887 (2004-02-01), Pillutla et al.
patent: 2004/0038303 (2004-02-01), Unger
patent: 2004/0137071 (2004-07-01), Unger
patent: 2004/0142381 (2004-07-01), Hubbard et al.
patent: WO88/08715 (1988-11-01), None
patent: WO 93/21939 (1993-11-01), None
patent: WO 01/93900 (2001-12-01), None
patent: WO 02/49672 (2002-06-01), None
patent: WO 03/074551 (2003-09-01), None
Laakoki et al, J Biol Chem, vol. 275, p. 10009-15, 2000.
Laakoki et al, FEBS, vol. 420, p. 97-102, 1997.
sequence alignment, 2009.
sequence search result, 2010.
Carlsson et al Biochem J. vol. 173, p. 723-737, 1978.
seqeunce search result ID No. 4 and 9, 2009.
seqeunce search result-1 (application '627), 2009.
seqeunce search result-2 (application '623), 2009.
Sequence alignment, 2009.
Grothey, A. et al., 1999. The role of insulin-like growth factor I and its receptor in cell growth, transformation, apoptosis, and chemoresistance in solid tumors. J. Cancer Res. Clin. Oncol. 125:166-173.
Ayre SG, Garcia y Bellon DP, Garcia DP Jr. 2000. Insulin, chemotherapy, and the mechanisms of malignancy: the design and the demise of cancer,Medical Hypotheses55:330-334.
Abita JP, Gauville C, Balitrand N, Gespach C, Canivet J. 1984, Binding of 125I-insulin to the human histiocytic lymphoma cell line U-937: effect of differentiation with retinoic acid.Leuk Res. 8(2):213-21.
Alabaster O, Vonderhaar BK, Shafie SM. 1981. Metabolic modification by insulin enhances methotrexate cytotoxicity in MCF-7 human breast cancer cells.Eur J Cancer Clin Oncol. 17(11):1223-8.
Schilsky RL, Bailey BD, Chabner BA. 1981. Characteristics of membrane transport of methotrexate by cultured human breast cancer cells.Biochem Pharmacol. 30(12):1537-42.
Oster JB, Creasey WA. 1981. Enhancement of cellular uptake of ellipticine by insulin preincubation.Eur J Cancer Clin Oncol. 17(10):1097-103.
Daughaday WH, Rotwein P. 1989. Insulin-like growth factors I and II. Peptide, messenger ribonucleic acid and gene structures, serum, and tissue concentrations.Endocr Rev. 10(1):68-91.
Stewart CE, Rotwein P. 1996. Growth, differentiation, and survival: multiple physiological functions for insulin-like growth factors.Physiol Rev. Oct. 1996;76(4):1005-26.
Yakar S, Wu Y, Setser J, Rosen CJ. 2002. The role of circulating IGF-I: lessons from human and animal models. Endocrine. 19(3):239-48.
Shackney SE, McCormack GW, Cuchural GJ Jr. 1978. Growth rate patterns of solid tumors and their relation to responsiveness to therapy: an analytical review.Ann. Intern. Med. 89:107-21.
Poznansky MJ, Singh R, Singh B, Fantus G. 1984. Insulin: carrier potential for enzyme and drug therapy.Science223(4642):1304-6.
Bures L, Bostik J, Motycka K, Spundova M, Rehak L. 1988. The use of protein as a carrier of methotrexate for experimental cancer chemotherapy. III. Human serum albumin-methotrexate derivative, its preparation and basic testing.Neoplasma35:329-42.
Ciftci K, Su J, Trovitch PB. 2003. Growth factors and chemotherapeutic modulation of breast cancer cells.J Pharm Pharmacol55(8):1135-41.
Francis GL, Ross M, Ballard FJ, Milner SJ, Senn C, McNeil KA, Wallace JC, King R, Wells JR. 1992. Novel recombinant fusion protein analogues of insulin-like growth factor (IGF)-I indicate the relative importance of IGF-binding protein and receptor binding for enhanced biological potency.J Mol. Endocrinol. 8(3):213-23.
Tomas FM, Knowles SE, Chandler CS, Francis GL, Owens PC, Ballard FJ. 1993. Anabolic effects of insulin-like growth factor-I (IGF-I) and an IGF-I variant in normal female rats.J Endocrinol. 137(3):413-21.
Stehle G, Sinn H, Wunder A, Schrenk HH, Schutt S, Maier-Borst W, Heene DL. 1997. The loading rate determines tumor targeting properties of methotrexate-albumin conjugates in rats.Anticancer Drugs8(7):677-85.
McTavish et al., Novel insulin-like growth factor-methotrexate covalent conjugate inhibits tumor growth . . . Translational Research (2009) 153:275-282.
Helms Larry R.
IGF Oncology, LLC
McTavish Hugh
Yao Lei
LandOfFree
Compounds and methods for treating cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds and methods for treating cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds and methods for treating cancer will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4220947